Synapse - Martin Tallman

Results (649)

Acquired resistance to BRAF inhibition in HCL is rare and retreatment with vemurafenib at relapse can induce high response rates: Final results of a phase II trial of vemurafenib in relapsed HCL

Meeting Abstract

Park, J. H.; Lee, J. O.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Vemuri, S.; Abdel-Wahab, O. I.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save

Metforminintreatment overcomes ATRA-resistance in acute promyelocytic leukemia FOXO3A expression

Meeting Abstract

Pereira-Martins, D. A.; Ortiz, C.; Franca-Neto, P. L.; Weinhauser, I.; Schiavinato, J. L.; Palma, P. V. B.; Bonaldo, C.; Koury, L. C. A.; Do Nascimento, M. C.; Melo, R. A. M.; more...
Blood (2018)

Fulltext@MSK | Save

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Meeting Abstract

King, A. C.; Pappacena, J.; Tallman, M. S.; Park, J. H.; Geyer, M. B.
Blood (2018)

Fulltext@MSK | Save

Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial (Alliance C10603)

Meeting Abstract

Jahn, N.; Panina, E.; Bullinger, L.; Dolnik, A.; Herzig, J.; Blätte, T. J.; Benner, A.; Krzykalla, J.; Gathmann, I.; Larson, R. A.; more...
Blood (2018)

Fulltext@MSK | Save

TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia

Meeting Abstract

Goldberg, A. D.; Talati, C.; Desai, P.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Sallman, D. A.; Lancet, J. E.; Roboz, G. J.; Sweet, K. L.; more...
Blood (2018)

Fulltext@MSK | Save

Characterization of novel subtypes in B progenitor acute lymphoblastic leukemia

Meeting Abstract

Gu, Z.; Churchman, M. L.; Roberts, K. G.; Moore, I.; Zhou, X.; Nakitandwe, J.; Hagiwara, K.; Pelletier, S.; Gingras, S.; Berns, H.; more...
Blood (2018)

Fulltext@MSK | Save

Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia

Meeting Abstract

Gaulin, C.; Chan, A.; Geyer, M. B.; Park, J. H.; Mantha, S.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save

Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial

Meeting Abstract

Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H.
Blood (2018)

Fulltext@MSK | Save

Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3-mutated AML